The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.00
Ask: 42.00
Change: -1.00 (-2.38%)
Spread: 2.00 (5.00%)
Open: 42.00
High: 42.00
Low: 41.00
Prev. Close: 42.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Frontier IP to host Portfolio Demo Day

6 Dec 2022 07:00

RNS Number : 6710I
Frontier IP Group plc
06 December 2022
 

Reach - a non-regulatory announcement

AIM: FIPP

06 December 2022

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Frontier IP to host Portfolio Demo Day at the Imperial War Museum, Duxford Cambridge

 

 

Frontier IP, a specialist in commercialising intellectual property, is holding a Portfolio Demo Day at the Imperial War Museum, Duxford, Cambridge ("IWM Duxford" or the "Museum") on the afternoon and evening of Tuesday 6th December 2022.

 

The event is an opportunity for some of Frontier IP's portfolio companies to present, demonstrate and discuss their new technologies to help tackle fundamental challenges, such as climate, energy, food, water and health.

 

Guests include investors, representatives of companies supported by Frontier IP, and industry partners. An afternoon session in the Museum's Marshall Auditorium will consist of presentations from portfolio companies, while the evening reception will give them the opportunity to showcase their technology. No new material information will be disclosed.

 

The portfolio companies presenting and demonstrating technologies are:

 

· Cambridge Raman Imaging is using graphene-based ultra-fast lasers and artificial intelligence in next generation Raman-imaging microscopes to research, diagnose and monitor diseases, such as cancers

 

· CamGraPhIC is developing graphene-based photonics with the potential to make data and telecommunications transmission much faster while using less energy

 

· Elute is showcasing its use of forensic linguistic algorithms for high-speed search and comparison of unstructured document datasets

 

· Celerum is demonstrating its novel artificial intelligence based on meta-heuristics, including nature-inspired computing, to make logistics more efficient, supporting efforts to improve the industry's carbon efficiency

 

· Nandi Proteins is discussing its customised ingredients based on vegetable and animal proteins. These can be used to replace undesirable ingredients such as fat, gluten and E-number additives in processed foods, or those that people do not want to consume - for example replacing animal proteins with vegetable proteins

 

· The Vaccine Group is developing novel herpesvirus-based vaccine platforms. Projects include those to tackle Lassa fever, African Swine Fever, Streptococcus suis and Porcine Reproductive and Respiratory Syndrome in animals, and COVID-19 in humans

 

· Pulsiv will be showing its patented technology to significantly improve the energy efficiency of power supplies, battery chargers, and LED lighting. It also extracts much more energy from photovoltaic solar cells, improving their output

 

· Alusid is creating premium-quality tiles and architectural surfaces from industrial waste.

 

· Des Solutio is developing safer and greener alternatives to the chemicals currently used to make beauty, pharmaceutical, personal healthcare and other products

 

· InSignals Neurotech is showing its patented technology to aid deep brain surgery on patients suffering neurological diseases, such as Parkinson's disease

 

· AquaInSilico is presenting its sophisticated software tools to optimise wastewater treatment, with potential applications spanning many different industries. It is a UN Ocean Innovator, working on a project to help protect and conserve one of the world's most diverse marine environments around the Cape Verde archipelago

 

· Liquid Graphene is a new spin-out company looking to exploit graphene-based inks to reduce the cost of solar cell manufacture and use

 

 

Frontier IP Chief Executive Officer Neil Crabb said: "We are looking forward to demonstrating the exciting technologies being developed by our portfolio companies and the role they have to play in helping to meet some of the serious challenges posed by climate change, water, food and energy."

 

 

 

 

 

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive Officer

Andrew Johnson, Communications and investor relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

 

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

 

 

T: 0203 328 5656

 

 

 

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAVELFBLLLXFBB
Date   Source Headline
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.